RARA CRAFT DATABASE for FDA Medical Devices
510(k)K153192

FDA DEVICE FACTS

Chemtrue Multi-Panel Drug Screen Dip Card/Cup Tests, Chemtrue Multi-Panel Drug Screen Dip Card/Cup with OPI 2000 Tests

Chemtron Biotech, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEApril 18, 2016PRODUCT CODEDJG

Indications for use

Chemtrue® Multi-Panel Drug Screen Cup with OPI 2000 Tests The Chemtrue® Multi-Panel Drug Screen Cup Tests are rapid lateral flow immunoassays for the qualitative detection of Amphetamine, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Marijuana, Methamphetamine, Morphine, Phencyclidine, Ecstasy, Methadone, Oxycodone, Propoxyphene and Tricyclic Antidepressants (TCA) drugs in human urine. The test cut-off concentrations and the compounds the tests are calibrated to are as follows: Analyte Abbreviation Calibrator Cutoff Concentration (ng/mL) Amphetamine AMP d-Amphetamine 300 Amphetamine AMP d-Amphetamine 500 Amphetamine AMP d-Amphetamine 1000 Barbiturates BAR Secobarbital/Pentobarbital 200 Barbiturates BAR Secobarbital/Pentobarbital 300 Benzodiazepines BZO Oxazepam 200 Benzodiazepines BZO Oxazepam 300 Buprenorphine BUP Buprenorphine 10 Cocaine COC Benzoylecgonine 150 Cocaine COC Benzoylecgonine 300 Ecstasy MDMA d,l-Methylenedioxy methamphetamine 500 Methamphetamine MET d-Methamphetamine 300 Methamphetamine MET d-Methamphetamine 500 Methamphetamine MET d-Methamphetamine 1000 Marijuana THC 11-nor-Δ9-THC-9-COOH 50 Methadone MTD Methadone 300 Opiates OPI Morphine 2000 Oxycodone OXY Oxycodone 100 Phencyclidine PCP Phencyclidine 25 Propoxyphene PPX Propoxyphene 300 Tricyclic Antidepressants TCA Nortriptyline 1000 The multi test panels can consist of up to fourteen (14) of the above listed analytes in any combination. Only one cutoff concentration will be included per analyte per device. The tests are intended for prescription and Over-The-Counter (OTC) use. The tests provide only a preliminary result. A more specific alternative chemical method must be used in order to obtain a confirmed assay result. Gas Chromatography / Mass Spectrometry (GC/MS) or Liquid Chromatography / Mass Spectrometry (LC/MS) are the preferred confirmatory methods. Clinical consideration and professional judgment should be applied to any drugs of abuse test result, particularly when preliminary positive results are indicated. The tests are not intended to differentiate between drugs of abuse and prescription use of Benzodiazepines, Barbiturates, Buprenorphine, Oxycodone, Propoxyphene and Tricyclic Antidepressants. There are no uniformly recognized cut-off concentration levels for these drugs in urine. Chemtrue ® Multi-Panel Drug Screen Cup Tests The Chemtrue® Multi-Panel Drug Screen Cup Tests are rapid lateral flow immunoassays for the qualitative detection of Amphetamine, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Marijuana, Methamphetamine, Morphine, Phencyclidine, Ecstasy, Methadone, Oxycodone, Propoxyphene and Tricyclic Antidepressants (TCA) drugs in human urine. The test cut-off concentrations and the compounds the tests are calibrated to are as follows: Analyte Abbreviation Calibrator Cutoff Concentration (ng/mL) Amphetamine AMP d-Amphetamine 300 Amphetamine AMP d-Amphetamine 500 Amphetamine AMP d-Amphetamine 1000 Barbiturates BAR Secobarbital/Pentobarbital 200 Barbiturates BAR Secobarbital/Pentobarbital 300 Benzodiazepines BZO Oxazepam 200 Benzodiazepines BZO Oxazepam 300 Buprenorphine BUP Buprenorphine 10 Cocaine COC Benzoylecgonine 150 Cocaine COC Benzoylecgonine 300 Ecstasy MDMA d,l-Methylenedioxy methamphetamine 500 Methamphetamine MET d-Methamphetamine 300 Methamphetamine MET d-Methamphetamine 500 Methamphetamine MET d-Methamphetamine 1000 Marijuana THC 11-nor-Δ9-THC-9-COOH 50 Methadone MTD Methadone 300 Morphine MOR Morphine 300 Oxycodone OXY Oxycodone 100 Phencyclidine PCP Phencyclidine 25 Propoxyphene PPX Propoxyphene 300 Tricyclic Antidepressants TCA Nortriptyline 1000 The multi test panels can consist of up to fourteen (14) of the above listed analytes in any combination. Only one cutoff concentration will be included per analyte per device. The tests are intended for prescription and Over-The-Counter (OTC) use. The tests provide only a preliminary result. A more specific alternative chemical method must be used in order to obtain a confirmed assay result. Gas Chromatography / Mass Spectrometry (GC/MS) or Liquid Chromatography / Mass Spectrometry (LC/MS) are the preferred confirmatory methods. Clinical consideration and professional judgment should be applied to any drugs of abuse test result, particularly when preliminary positive results are indicated. The tests are not intended to differentiate between drugs of abuse and prescription use of Benzodiazepines, Barbiturates, Buprenorphine, Oxycodone, Propoxyphene and Tricyclic Antidepressants. There are no uniformly recognized cut-off concentration levels for these drugs in urine. Chemtrue ® Multi-Panel Drug Screen Dip Card with OPI2000 Tests The Chemtrue® Multi-Panel Drug Screen Dip Card Tests are rapid lateral flow immunoassays for the qualitative detection of Amphetamine, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Marijuana, Methamphetamine, Morphine, Phencyclidine, Ecstasy, Methadone, Oxycodone, Propoxyphene and Tricyclic Antidepressants (TCA) drugs in human urine. The test cut-off concentrations and the compounds the tests are calibrated to are as follows: Analyte Abbreviation Calibrator Cutoff Concentration (ng/mL) Amphetamine AMP d-Amphetamine 300 Amphetamine AMP d-Amphetamine 500 Amphetamine AMP d-Amphetamine 1000 Barbiturates BAR Secobarbital/Pentobarbital 200 Barbiturates BAR Secobarbital/Pentobarbital 300 Benzodiazepines BZO Oxazepam 200 Benzodiazepines BZO Oxazepam 300 Buprenorphine BUP Buprenorphine 10 Cocaine COC Benzoylecgonine 150 Cocaine COC Benzoylecgonine 300 Ecstasy MDMA d,l-Methylenedioxy methamphetamine 500 Methamphetamine MET d-Methamphetamine 300 Methamphetamine MET d-Methamphetamine 500 Methamphetamine MET d-Methamphetamine 1000 Marijuana THC 11-nor-Δ9-THC-9-COOH 50 Methadone MTD Methadone 300 Opiates OPI Morphine 2000 Oxycodone OXY Oxycodone 100 Phencyclidine PCP Phencyclidine 25 Propoxyphene PPX Propoxyphene 300 Tricyclic Antidepressants TCA Nortriptyline 1000 The multi test panels can consist of up to fourteen (14) of the above listed analytes in any combination. Only one cutoff concentration will be included per analyte per device. The tests are intended for prescription and Over-The-Counter (OTC) use. The tests provide only a preliminary result. A more specific alternative chemical method must be used in order to obtain a confirmed assay result. Gas Chromatography / Mass Spectrometry (GC/MS) or Liquid Chromatography / Mass Spectrometry (LC/MS) are the preferred confirmatory methods. Clinical consideration and professional judgment should be applied to any drugs of abuse test result, particularly when preliminary positive results are indicated. The tests are not intended to differentiate between drugs of abuse and prescription use of Benzodiazepines, Barbiturates, Buprenorphine, Oxycodone, Propoxyphene and Tricyclic Antidepressants. There are no uniformly recognized cut-off concentration levels for these drugs in urine. Chemtrue® Multi-Panel Drug Screen Dip Card Tests The Chemtrue® Multi-Panel Drug Screen Cup Tests are rapid lateral flow immunoassays for the qualitative detection of Amphetamine, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Marijuana, Methamphetamine, Morphine, Phencyclidine, Ecstasy, Methadone, Oxycodone, Propoxyphene and Tricyclic Antidepressants (TCA) drugs in human urine. The test cut-off concentrations and the compounds the tests are calibrated to are as follows: Analyte Abbreviation Calibrator Cutoff Concentration (ng/mL) Amphetamine AMP d-Amphetamine 300 Amphetamine AMP d-Amphetamine 500 Amphetamine AMP d-Amphetamine 1000 Barbiturates BAR Secobarbital/Pentobarbital 200 Barbiturates BAR Secobarbital/Pentobarbital 300 Benzodiazepines BZO Oxazepam 200 Benzodiazepines BZO Oxazepam 300 Buprenorphine BUP Buprenorphine 10 Cocaine COC Benzoylecgonine 150 Cocaine COC Benzoylecgonine 300 Ecstasy MDMA d,l-Methylenedioxy methamphetamine 500 Methamphetamine MET d-Methamphetamine 300 Methamphetamine MET d-Methamphetamine 500 Methamphetamine MET d-Methamphetamine 1000 Marijuana THC 11-nor-Δ9-THC-9-COOH 50 Methadone MTD Methadone 300 Morphine MOR Morphine 300 Oxycodone OXY Oxycodone 100 Phencyclidine PCP Phencyclidine 25 Propoxyphene PPX Propoxyphene 300 Tricyclic Antidepressants TCA Nortriptyline 1000 The multi test panels can consist of up to fourteen (14) of the above listed analytes in any combination. Only one cutoff concentration will be included per analyte per device. The tests are intended for prescription and Over-The-Counter (OTC) use. The tests provide only a preliminary result. A more specific alternative chemical method must be used in order to obtain a confirmed assay result. Gas Chromatography / Mass Spectrometry (GC/MS) or Liquid Chromatography / Mass Spectrometry (LC/MS) are the preferred confirmatory methods. Clinical consideration and professional judgment should be applied to any drugs of abuse test result, particularly when preliminary positive results are indicated. The tests are not intended to differentiate between drugs of abuse and prescription use of Benzodiazepines, Barbiturates, Buprenorphine, Oxycodone, Propoxyphene and Tricyclic Antidepressants. There are no uniformly recognized cut-off concentration levels for these drugs in urine.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 3, 2026